Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Davita Inc (DVA) vs Zscaler Inc (ZS) Price & Performance

Davita IncTrade
Zscaler IncTrade

Price performance (Past 24H)

Key statistics

Davita Inc vs Zscaler Inc — how do they compare? Davita Inc trades at $179.49 (market cap $11.38B), while Zscaler Inc trades at $176.38 (market cap $28.87B). The key difference: Zscaler Inc is far larger — about 2.5× Davita Inc's market cap, and Davita Inc is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals.

DVAZS
Market Cap
$11.38B$28.87B
Sector
HealthTechnology
52-Week High
$240.96$336.27
52-Week Low
$103.87$118.05
Enterprise Value
$24.10B$27.20B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Davita Inc

DaVita (DVA) trades at $183.69, down slightly by 0.04% over the past day. The stock shows strong fundamental performance with consistent earnings beats in recent quarters, including Q2 2026 EPS of $4.02 versus $3.88 expected (Zacks Investment Research, 2026-08-04). However, technical indicators signal a bearish trend, with the price near key support at $182. Revenue growth remains steady, climbing to $13.64 billion in 2025, though net income margin dipped to 5.47%.

The outlook is mixed; analyst consensus leans bullish with a $232.25 price target (MarketBeat, 2026-08-05), but risks include reimbursement pressure and high debt levels. Investment appeal hinges on execution against guidance amid payer-mix challenges, with the current valuation offering potential upside if operational trends stabilize.

Zscaler Inc

Zscaler (ZS) trades at $176.11, showing modest daily movement. The stock exhibits a bullish technical trend with strong analyst support, evidenced by 42 buy ratings and a consensus price target of $191.81. Recent earnings consistently beat expectations, with Q1 2026 EPS of $1.08 surpassing the $1.01 forecast. Revenue growth is robust, increasing from $1.1B in 2022 to $2.67B in 2025, though the company remains unprofitable with a net income margin of -2.44%.

The outlook is positive due to strong revenue growth, leadership in cloud security, and bullish analyst sentiment. Key risks include persistent unprofitability, high valuation multiples like a P/S of 8.94, and competitive pressures in the cybersecurity sector. The upcoming Q2 2026 earnings report on September 3, 2026, will be critical for validating growth trajectory and investor confidence.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Read more on DVA

About Zscaler Inc

Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.

Read more on ZS